{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:36:15Z","timestamp":1794746175673,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clinthera.2022.12.008","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T07:34:06Z","timestamp":1674286446000},"page":"55-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology"],"prefix":"10.1016","volume":"45","author":[{"given":"Neeta B.","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi R.","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Somayaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-2034","authenticated-orcid":false,"given":"Robert","family":"Dullea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.12.008_bib0001","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep4.1935","article-title":"Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017\u20132018 transient elastography data and application of machine learning","volume":"6","author":"Noureddin","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0002","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0004","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0007","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","article-title":"Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis","volume":"49","author":"Yen","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0008","doi-asserted-by":"crossref","first-page":"13018","DOI":"10.1073\/pnas.95.22.13018","article-title":"Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis","volume":"95","author":"Cases","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0009","doi-asserted-by":"crossref","first-page":"38870","DOI":"10.1074\/jbc.M106219200","article-title":"Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members","volume":"276","author":"Cases","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/ATVBAHA.114.304584","article-title":"Roles of acyl-CoA:diacylglycerol acyltransferases 1 and 2 in triacylglycerol synthesis and secretion in primary hepatocytes","volume":"35","author":"Li","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2018.08.001","article-title":"Role of DGAT enzymes in triacylglycerol metabolism","volume":"655","author":"Bhatt-Wessel","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0012","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1756-0500-4-249","article-title":"Structure-function analysis of diacylglycerol acyltransferase sequences from 70 organisms","volume":"4","author":"Cao","year":"2011","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0013","doi-asserted-by":"crossref","first-page":"40273","DOI":"10.1074\/jbc.M607986200","article-title":"Membrane topology and identification of key functional amino acid residues of murine acyl-CoA:diacylglycerol acyltransferase-2","volume":"281","author":"Stone","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0014","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41586-020-2289-6","article-title":"Structure and catalytic mechanism of a human triacylglycerol-synthesis enzyme","volume":"581","author":"Sui","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0015","doi-asserted-by":"crossref","first-page":"37377","DOI":"10.1074\/jbc.M110.163691","article-title":"Topological orientation of acyl-CoA:diacylglycerol acyltransferase-1 (DGAT1) and identification of a putative active site histidine and the role of the n terminus in dimer\/tetramer formation","volume":"285","author":"McFie","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0016","doi-asserted-by":"crossref","first-page":"36238","DOI":"10.1074\/jbc.M111.251900","article-title":"Evidence that diacylglycerol acyltransferase 1 (DGAT1) has dual membrane topology in the endoplasmic reticulum of HepG2 cells","volume":"286","author":"Wurie","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0017","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-0854.2007.00689.x","article-title":"Imaging of lipid biosynthesis: how a neutral lipid enters lipid droplets","volume":"9","author":"Kuerschner","year":"2008","journal-title":"Traffic"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0018","doi-asserted-by":"crossref","first-page":"28235","DOI":"10.1074\/jbc.M111.256008","article-title":"Murine diacylglycerol acyltransferase-2 (DGAT2) can catalyze triacylglycerol synthesis and promote lipid droplet formation independent of its localization to the endoplasmic reticulum","volume":"286","author":"McFie","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0019","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1074\/jbc.M805768200","article-title":"The endoplasmic reticulum enzyme DGAT2 is found in mitochondria-associated membranes and has a mitochondrial targeting signal that promotes its association with mitochondria","volume":"284","author":"Stone","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbalip.2018.06.008","article-title":"Diacylglycerol acyltransferase-2 contains a c-terminal sequence that interacts with lipid droplets","volume":"1863","author":"McFie","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0021","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1194\/jlr.M020156","article-title":"The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2","volume":"53","author":"Qi","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0022","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/j.1742-4658.2012.08684.x","article-title":"Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized fatty acids in HepG2 cells","volume":"279","author":"Wurie","year":"2012","journal-title":"FEBS J"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0023","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1083\/jcb.201201139","article-title":"The FATP1-DGAT2 complex facilitates lipid droplet expansion at the ER-lipid droplet interface","volume":"198","author":"Xu","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0024","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.devcel.2013.01.013","article-title":"Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets","volume":"24","author":"Wilfling","year":"2013","journal-title":"Dev Cell"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.22980","article-title":"Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids","volume":"50","author":"Villanueva","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0026","doi-asserted-by":"crossref","first-page":"11767","DOI":"10.1074\/jbc.M311000200","article-title":"Lipopenia and skin barrier abnormalities in DGAT2-deficient mice","volume":"279","author":"Stone","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0027","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1194\/jlr.M093112","article-title":"The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes","volume":"60","author":"Chitraju","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0028","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0029","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2017.07.012","article-title":"Triglyceride synthesis by DGAT1 protects adipocytes from lipid-induced ER stress during lipolysis","volume":"26","author":"Chitraju","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0030","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1194\/jlr.M029041","article-title":"Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying","volume":"53","author":"Ables","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0031","doi-asserted-by":"crossref","first-page":"eaav9701","DOI":"10.1126\/scitranslmed.aav9701","article-title":"Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis","volume":"11","author":"Amin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0032","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0033","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.1021\/acs.jmedchem.5b01006","article-title":"Discovery and optimization of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2)","volume":"58","author":"Futatsugi","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0034","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbalip.2008.01.001","article-title":"Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice","volume":"1781","author":"Liu","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0036","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.30765","article-title":"Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice","volume":"70","author":"Gluchowski","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0037","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1021\/acs.jmedchem.5b01345","article-title":"Discovery and pharmacology of a novel class of diacylglycerol acyltransferase 2 inhibitors","volume":"58","author":"Imbriglio","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0038","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1039\/C6MD00564K","article-title":"Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile","volume":"8","author":"Futatsugi","year":"2016","journal-title":"Medchemcomm"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0039","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.omtn.2017.07.003","article-title":"Strategies for in vivo screening and mitigation of hepatotoxicity associated with antisense drugs","volume":"8","author":"Kamola","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0041","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1172\/JCI64873","article-title":"DGAT1 mutation is linked to a congenital diarrheal disorder","volume":"122","author":"Haas","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0042","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1194\/jlr.P075119","article-title":"Identification and characterization of a novel DGAT1 missense mutation associated with congenital diarrhea","volume":"58","author":"Gluchowski","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0043","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0044","first-page":"1253A","article-title":"Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on liver fat content in nonalcoholic fatty liver disease","volume":"62","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacl.2015.03.066","article-title":"The diacylglycerol acyltransferase 1 inhibitor, pradigastat, was well tolerated in a 52-week clinical trial in FCS patients","volume":"9","author":"Stroes","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0046","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/dom.12221","article-title":"Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial","volume":"16","author":"Denison","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0047","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/dom.12002","article-title":"Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study","volume":"15","author":"Denison","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0048","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0049","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in >300,000 individuals","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0050","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.cmet.2018.04.004","article-title":"DGAT2 inhibition alters aspects of triglyceride metabolism in rodents but not in non-human primates","volume":"27","author":"McLaren","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0051","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0052","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0053","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0054","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.4254\/wjh.v7.i18.2155","article-title":"Advances in hepatocellular carcinoma: nonalcoholic steatohepatitis-related hepatocellular carcinoma","volume":"7","author":"Khan","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease \u2013 meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0056","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0057","first-page":"40","article-title":"Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail","volume":"9","author":"Sharma","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0058","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14656566.2020.1744564","article-title":"Current and new pharmacotherapy options for non-alcoholic steatohepatitis","volume":"21","author":"Sumida","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0059","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of nonalcoholic fatty liver disease: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single center experience in 91 patients","volume":"12","author":"Padole","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0061","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/CS20180306","article-title":"Atherosclerosis and inflammation: overview and updates","volume":"132","author":"Geovanini","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0062","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.13620","article-title":"Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis","volume":"43","author":"Noureddin","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056159","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0064","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1021\/acs.jmedchem.2c01200","article-title":"Discovery of ervogastat (PF-06865571): a potent and selective inhibitor of diacylglycerol acyltransferase 2 for the treatment of non-alcoholic steatohepatitis","volume":"65","author":"Futatsugi","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2022.12.008_bib0065","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","volume":"132","author":"Mora","year":"2015","journal-title":"Circulation"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822004143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822004143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:48Z","timestamp":1758963468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822004143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0149291822004143"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.12.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}